Yosuke Kuroda
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Research Interests
Yosuke Kuroda has a total of 23 co-authors. Here are the top co-authors by number of shared publications:
- Atsushi Fujii
Department of Surgery, Kyushu University Beppu Hospital, 4546 Tsurumihara, Beppu 874-0838, Japan
1 shared publication - Hajime Otsu
Department of Surgery, Kyushu University Beppu Hospital, 4546 Tsurumihara, Beppu 874-0838, Japan
1 shared publication - Hidetoshi Eguchi
Department of Surgery, Kyushu University Beppu Hospital, 4546 Tsurumihara, Beppu 874-0838, Japan
1 shared publication - Hiroaki Ueo
Ueo Breast Surgical Hospital, 188-2 Haya, Oita 870-0854, Japan
1 shared publication - Hiroki Ueo
Ueo Breast Cancer Hospital, Oita, Japan
1 shared publication - Ippei Kawada
Department of Surgery, Japanese Red Cross Oita Hospital, Oita, Japan
1 shared publication
Latest Publications
- 9 February 2026
- Published by Springer Nature in Surgery Today
- Vol. 56 (7) , 1387-1394
Postoperative outcomes of pancreatoduodenectomy for pancreatic head malignancy in patients over 85 years of age: A safety evaluation using propensity score matching
Introduction As the global population ages, older patients undergo pancreatoduodenectomy (PD). This study aimed to evaluate the safety and postoperative outcomes of PD in patients > 85 years of age. Methods We reviewed 200 consecutive PDs and compared the postoperative outcomes in patients aged ≥ 85 years using propensity score matching (PSM). Results After PSM, no differences in the clinical characteristics were observed between the two cohorts (n = 16 each). Those aged ≥ 85 years had a significantly lower induction rate of adjuvant chemotherapy (p < 0.0001) and a higher rate of best supportive care selection at recurrence (BSC) (p = 0.033) than those aged < 85 years. There was no significant difference in the rate of non-cancer-related deaths (p = 0.18). Although there were no significant differences in the -free survival rates (p = 0.89), the overall survival rate of those ≥ 85 years was significantly worse (p = 0.023). The risk factors for death after surgery were tumor-related factors and BSC (p = 0.0012). An age ≥ 85 years was not a risk factor for major postoperative complications or death after surgery. Conclusions PD can be safely performed in patients aged ≥ 85 years without increasing postoperative complications and recurrences in the cases with appropriate patient selection.
- 9 February 2026
- Published by Springer Nature in Surgery Today
- Vol. 56 (7) , 1387-1394
Postoperative outcomes of pancreatoduodenectomy for pancreatic head malignancy in patients over 85 years of age: A safety evaluation using propensity score matching
Introduction As the global population ages, older patients undergo pancreatoduodenectomy (PD). This study aimed to evaluate the safety and postoperative outcomes of PD in patients > 85 years of age. Methods We reviewed 200 consecutive PDs and compared the postoperative outcomes in patients aged ≥ 85 years using propensity score matching (PSM). Results After PSM, no differences in the clinical characteristics were observed between the two cohorts (n = 16 each). Those aged ≥ 85 years had a significantly lower induction rate of adjuvant chemotherapy (p < 0.0001) and a higher rate of best supportive care selection at recurrence (BSC) (p = 0.033) than those aged < 85 years. There was no significant difference in the rate of non-cancer-related deaths (p = 0.18). Although there were no significant differences in the -free survival rates (p = 0.89), the overall survival rate of those ≥ 85 years was significantly worse (p = 0.023). The risk factors for death after surgery were tumor-related factors and BSC (p = 0.0012). An age ≥ 85 years was not a risk factor for major postoperative complications or death after surgery. Conclusions PD can be safely performed in patients aged ≥ 85 years without increasing postoperative complications and recurrences in the cases with appropriate patient selection.
- Open Access
- 14 January 2020
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 21 (2) , 511
N-Cadherin mRNA Levels in Peripheral Blood Could Be a Potential Indicator of New Metastases in Breast Cancer: A Pilot Study
Background: There is growing evidence that patients with metastatic breast cancer whose disease progresses from a new metastasis (NM) have a worse prognosis than that of patients whose disease progresses from a pre-existing metastasis. The aim of this pilot study is to identify a blood biomarker predicting NM in breast cancer. Methods: The expression of epithelial (cytokeratin 18/19) or mesenchymal (plastin-3, vimentin, and N-cadherin) markers in the peripheral blood (PB) of recurrent breast cancer patients undergoing chemotherapy with eribulin or S-1 was measured over the course of treatment by RT-qPCR. The clinical significance of preoperative N-cadherin expression in the PB or tumor tissues of breast cancer patients undergoing curative surgery was assessed by RT-qPCR or using public datasets. Finally, N-cadherin expression in specific PB cell types was assessed by RT-qPCR. Results: The expression levels of the mesenchymal markers N-cadherin and vimentin were high in the NM cases, whereas that of the epithelial marker cytokeratin 18 was high in the pre-existing metastasis cases. High preoperative N-cadherin expression in PB or tumor tissues was significantly associated with poor recurrence-free survival. N-cadherin was expressed mainly in polymorphonuclear leukocytes in PB. Conclusion: N-cadherin mRNA levels in blood may serve as a novel prognostic biomarker predicting NM, including recurrence, in breast cancer patients.
- 14 January 2020
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 21 (2) , 511
Open AccessN-Cadherin mRNA Levels in Peripheral Blood Could Be a Potential Indicator of New Metastases in Breast Cancer: A Pilot Study
Background: There is growing evidence that patients with metastatic breast cancer whose disease progresses from a new metastasis (NM) have a worse prognosis than that of patients whose disease progresses from a pre-existing metastasis. The aim of this pilot study is to identify a blood biomarker predicting NM in breast cancer. Methods: The expression of epithelial (cytokeratin 18/19) or mesenchymal (plastin-3, vimentin, and N-cadherin) markers in the peripheral blood (PB) of recurrent breast cancer patients undergoing chemotherapy with eribulin or S-1 was measured over the course of treatment by RT-qPCR. The clinical significance of preoperative N-cadherin expression in the PB or tumor tissues of breast cancer patients undergoing curative surgery was assessed by RT-qPCR or using public datasets. Finally, N-cadherin expression in specific PB cell types was assessed by RT-qPCR. Results: The expression levels of the mesenchymal markers N-cadherin and vimentin were high in the NM cases, whereas that of the epithelial marker cytokeratin 18 was high in the pre-existing metastasis cases. High preoperative N-cadherin expression in PB or tumor tissues was significantly associated with poor recurrence-free survival. N-cadherin was expressed mainly in polymorphonuclear leukocytes in PB. Conclusion: N-cadherin mRNA levels in blood may serve as a novel prognostic biomarker predicting NM, including recurrence, in breast cancer patients.